Company profile
Curis, Inc.
NASDAQ: CRIS · Healthcare · Biotechnology
#640 of 1,418 Healthcare companies by revenue31st-percentile growth
EA Score
53DFH 35DQ 79GM 52SS 54
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ Piotroski F, Altman-Z
Methodology →Revenue TTM
$7.1M
Rev growth YoY (TTM)
-36.9%
Net income (FY)
-$7.6M
Employees
22
as of 2026-08-24
Market cap
$3.1M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.4M$9.4M2025
Net income-$7.6M-$7.6M2025
Operating income-$5.7M-$5.7M2025
Total assets$20.0M$20.0M2025
Liabilities$14.5M$14.5M2025
Equity$5.5M$5.5M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Curis, Inc.’s revenue?
Curis, Inc. booked $9.4M in FY2025 revenue, contracting 13% year over year — slower than 69% of Healthcare companies we track, at a -80.3% net margin.
Peers · Healthcare
Delivra Health Brands Inc.55CYulong Eco-Materials Limited——ThermoGenesis Holdings, Inc.——Rafarma Pharmaceuticals, Inc.71BInternational Stem Cell Corporation57CNeuroOne Medical Technologies Corporation55CNeighbors
Middlesex →Key facts
CEOJames Dentzer
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeNASDAQ: CRIS
Employees22
IPO date2000-08-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.